Surmodics (NASDAQ:SRDX) Rating Lowered to D at TheStreet

Surmodics (NASDAQ:SRDXGet Rating) was downgraded by research analysts at TheStreet from a “c” rating to a “d” rating in a report released on Friday, TheStreetRatingsTable reports.

Several other research firms also recently weighed in on SRDX. StockNews.com started coverage on Surmodics in a research report on Thursday, March 31st. They set a “hold” rating for the company. Needham & Company LLC decreased their price objective on shares of Surmodics from $70.00 to $58.00 and set a “buy” rating for the company in a report on Friday, February 4th.

Surmodics stock opened at $37.95 on Friday. The stock has a market cap of $530.39 million, a price-to-earnings ratio of -50.60 and a beta of 1.02. Surmodics has a 1-year low of $36.24 and a 1-year high of $62.27. The stock has a 50-day moving average price of $42.65.

Surmodics (NASDAQ:SRDXGet Rating) last issued its quarterly earnings results on Wednesday, April 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.10. Surmodics had a negative return on equity of 6.22% and a negative net margin of 10.80%. During the same period in the prior year, the business earned $0.62 EPS. On average, equities research analysts forecast that Surmodics will post -1.15 EPS for the current fiscal year.

In other Surmodics news, CEO Gary R. Maharaj sold 4,000 shares of the firm’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $44.99, for a total transaction of $179,960.00. Following the transaction, the chief executive officer now directly owns 155,041 shares in the company, valued at approximately $6,975,294.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of SRDX. Sphinx Trading LP bought a new stake in shares of Surmodics in the 4th quarter valued at about $39,000. Cubist Systematic Strategies LLC purchased a new position in Surmodics during the fourth quarter valued at approximately $53,000. Marshall Wace LLP purchased a new position in Surmodics during the fourth quarter valued at approximately $83,000. Captrust Financial Advisors raised its stake in Surmodics by 230.0% in the third quarter. Captrust Financial Advisors now owns 1,828 shares of the company’s stock worth $102,000 after buying an additional 1,274 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in Surmodics during the fourth quarter worth $144,000. 94.40% of the stock is currently owned by institutional investors and hedge funds.

Surmodics Company Profile (Get Rating)

Surmodics, Inc, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).

Further Reading

Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.